SETH LEDERMAN - 28 Sep 2021 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Issuer symbol
TNXP
Transactions as of
28 Sep 2021
Transactions value $
$7,320
Form type
4
Filing time
28 Sep 2021, 17:04:03 UTC
Next filing
17 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNXP Common Stock, $0.001 par value Purchase $7,320 +12,000 +6780% $0.6100 12,177 28 Sep 2021 Direct
holding TNXP Common Stock, $0.001 par value 135,000 28 Sep 2021 By 401(k) plan
holding TNXP Common Stock, $0.001 par value 459 28 Sep 2021 By IRA Account
holding TNXP Common Stock, $0.001 par value 31 28 Sep 2021 By spouse
holding TNXP Common Stock, $0.001 par value 30 28 Sep 2021 By Leder Laboratories, Inc. F1
holding TNXP Common Stock, $0.001 par value 30 28 Sep 2021 By Starling Pharmaceuticals, Inc. F1
holding TNXP Common Stock, $0.001 par value 205 28 Sep 2021 By Lederman & Co., LLC F1
holding TNXP Common Stock, $0.001 par value 33 28 Sep 2021 By L&L Technologies, LLC F1
holding TNXP Common Stock, $0.001 par value 59 28 Sep 2021 By Targent Pharmaceuticals, LLC F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reporting person may be deemed to be a control person of this entity.